Heranova unveils revolutionary non-invasive endometriosis test, HerResolve, at Ovarian Club Asian Conference

92% diagnostic accuracy through only a blood test gives early diagnosis and treatment of endometriosis

Medical technology innovator Heranova, announced a non-invasive test for endometriosis -- HerResolve™ -- during the 2024 Ovarian Club Asian Conference at the Hong Kong Convention and Exhibition Centre, in December.

The innovative test aims to transform the diagnosis and management of endometriosis, a common and debilitating condition affecting millions of women worldwide. It has historically presented diagnostic challenges often requiring a laparoscopic surgical procedure requiring patients to receive general anaesthesia.

The HerResolve™ blood test achieves an impressive 92% diagnostic accuracy. And so, offers a non-invasive alternative for women experiencing the persistent and chronic symptoms of the condition such as pelvic pain, and pain during menstruation, and more seriously infertility.

The HerResolve™ technology identifies clinically significant miRNA biomarkers and uses proprietary AI algorithms and bioinformatics to give clear ‘positive/negative’ results. This provides physicians with reliable and efficient diagnostic information.

“We recognise the complexity and urgency of diagnosing endometriosis,” said Dr. Jonathan Zhao, CEO of Heranova.

“HerResolve™ will transform the landscape, enabling early and precise identification of the condition to empower physicians [working in] gynaecological medicine.”

Heranova is a medical technology company delivering innovative solutions for women's health challenges. It integrates diagnostics, therapeutics, medical devices with data analysis, to provide solutions for unmet obstetrics and gynaecological needs. Founded in March 2022 in Boston, MA., USA, Heranova operates on a US-Asia joint model, to conduct its research, development and delivery to the marketplace.

-- PRNewswire / Heranova Lifesciences, Inc.